Moderna just handed back 7% of its staggering year-to-date run in a single session, and the question rattling traders is whether this is a routine exhale or the beginning of a painful…
A top Barclays biopharma analyst says the forces that froze biotech dealmaking are breaking apart, and the pharma giants shopping for acquisitions have very specific reasons they cannot afford to stop.
Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.
Moderna's mRNA cancer vaccine sent shares on one of biotech's wildest two-day rides in years, but the brutal Thursday reversal raises a question investors now have to answer: does the science justify…
Hedge funds are quietly loading up on a battered pharma giant while yield hunters circle its once-near-7% dividend, but with a 14% rally already in the books and patent cliffs looming, the…
A historic one-session rally in a cancer vaccine stock is already unwinding, and Wall Street analysts disagree sharply on whether the reversal reflects a trade gone cold or an opportunity that the…
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly…
Tempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.
A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have…
FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.
Moderna has already surged more than 80% in 2026, but two major events packed into the next two weeks could either cement that rally or unravel it fast.
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story…
